Strong recent study results for an experimental Alzheimer’s treatment have exposed a gap between the changes such drugs can make in the brain and their potential limits in alleviating symptoms of the debilitating disease.
Lecanemab cleared accumulations in the brain of beta-amyloid, sticky protein fragments that researchers have long suspected contribute to Alzheimer’s, drugmakers Biogen and Eisai said last month. The drug also slowed the disease’s progression compared with placebo, reducing cognitive decline by 27%, the companies said.
